Deerfield Management Company, L.P. (Series C) Revance Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

  • $5.38 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
BUY
$24.7 - $37.61 $21.5 Million - $32.7 Million
870,000 New
870,000 $22 Million
Q1 2020

May 15, 2020
SELL
$12.46 - $27.81 $11.2 Million - $25 Million
-900,000 Closed
0 $0
Q4 2019

Feb 14, 2020
BUY
$11.66 - $20.15 $10.5 Million - $18.1 Million
900,000 New
900,000 $14.6 Million
Q1 2018

May 15, 2018
SELL
$29.15 - $37.4 $29.2 Million - $37.4 Million
-1,000,000 Closed
0 $0
Q4 2017

Feb 14, 2018
BUY
$24.55 - $36.3 $24.6 Million - $36.3 Million
1,000,000
1,000,000 $35.8 Million

Others Institutions Holding RVNC

# of Institutions
234
Shares Held
82.8M
Call Options Held
680K
Put Options Held
896K
View Full List

About Revance Therapeutics, Inc.

RVNC Quotes by TradingView
  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Deerfield Management Company, L.P. (Series C) Portfolio

Follow Deerfield Management Company, L.P. (Series C) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email